Sotera Health Company (SHC) Stock Price & How to Invest

Sotera Health provides the step a medical product has to pass before it can be sold: killing whatever is living on it. Sterigenics, the largest of the three units, runs contract sterilization plants using gamma irradiation, ethylene oxide and electron beam, and has done that work for more than 90 years. Nordion supplies the cobalt-60 that makes gamma sterilization possible, along with the irradiator systems that house it, and the company estimates gamma handles roughly 30% of single-use medical device sterilization worldwide. Nelson Labs sells microbiological and analytical chemistry testing (over 900 distinct tests) plus the regulatory advisory work customers need to validate a sterilization method and defend it to a regulator. Revenue for the twelve months to June 30, 2026 was ~$1.22 billion across 62 facilities and more than 3,000 employees. The customer list is concentrated at the top of the industry: over 40 of the top 50 medical device companies and nine of the ten largest global pharmaceutical companies. More than 90% of both Sterigenics and Nordion revenue in 2025 came from customers on multi-year contracts, so volumes track device production rather than any discretionary spending cycle.

Pricing and volume are the two levers the numbers turn on, and both worked in the first half of 2026. Second-quarter revenue rose 9.2% to $321.4 million, with Sterigenics up 8.6%, Nordion up 15.8% on the timing of cobalt-60 harvests, and Nelson Labs up 6.3% after a weak 2025. Adjusted EBITDA margin reached 51.6% in the quarter, a level very few healthcare-services businesses hold, and management raised full-year guidance on August 6, 2026 to $1.236 billion to $1.254 billion of revenue and $634 million to $643 million of adjusted EBITDA. The capital structure explains much of the equity story. Sotera carried ~$2.27 billion of total debt against $357.0 million of cash at June 30, 2026, and net leverage of 3.0x reached the top of the company's long-term target range for the first time. A May 2026 term loan repricing cut the spread by 25 basis points and saves ~$3.5 million a year. At ~$19.57 a share the equity is worth ~$5.58 billion, or roughly 12x trailing adjusted EBITDA on an enterprise value near $7.5 billion. The gap between that multiple and what infrastructure-like healthcare assets usually fetch is where the ethylene oxide tort docket sits.

The ethylene oxide tort docket is the dominant, partly quantified risk. Sterigenics and affiliates have already agreed to pay $408.0 million to settle over 880 Willowbrook, Illinois claims (term sheets January 2023, finalized June 2023), $35 million for 79 Atlanta claims in October 2023, $30.9 million for 97 more Illinois claims in April 2025 and $34.0 million for 129 further Illinois claims in July 2025. A single Cook County jury returned a $358.7 million verdict in 2022, of which $320 million was punitive. As of July 31, 2026 the open inventory was approximately 500 Georgia personal-injury and wrongful-death claims, ~305 Georgia property-devaluation suits, ~150 California claims tied to the Vernon facilities with initial trials scheduled for January and April 2027, and ~15 Illinois cases. The company states that losses in the remaining cases are not probable and carries no reserve for them, so an adverse verdict would land unprovided for. Georgia rulings currently favor the defense, since the trial court excluded plaintiffs' general causation experts and entered summary judgment in March 2026, but those rulings are on appeal. Regulation is the second exposure. The EPA's March 2024 NESHAP rules require permanent total enclosure capture, higher control efficiencies and continuous emissions monitoring at ethylene oxide sterilizers. A July 2025 Clean Air Act proclamation granted Sotera's facilities a two-year exemption, and a January 2026 suit in the District of Columbia seeks to invalidate that exemption and restore the original deadline. Capital expenditure guidance of $200 million to $225 million for 2026, against ~$1.24 billion of revenue, reflects part of that compliance burden and keeps free cash flow far below adjusted EBITDA. A separate FIFRA interim decision issued in January 2025 phases in tighter worker exposure limits over one to ten years. Three smaller items sit behind those. Total debt of ~$2.27 billion against $665.6 million of book equity leaves limited cushion if volumes stall. The United States has a single industry supplier of ethylene oxide. And Nelson Labs shrank 3.9% in 2025 and grew only 0.9% in constant currency in the first half of 2026, a reminder that the testing unit does not behave like the sterilization ones.

9 analysts publish price targets on SHC, averaging $22.72 against a $19.57 price as of August 2026, or +16.1%. The published targets run from $18.00 to $25.00, a moderate spread, and the ratings split 8 buy, 2 hold, 0 sell. Over the last six months there have been 5 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full SHC forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Sotera Health Company. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Contracted volume and repeat pricing. More than 90% of Sterigenics revenue and roughly 90% of Nordion revenue in 2025 came from customers under multi-year contracts, many carrying variable price clauses. The most optimistic published target, $25.00, assumes this works close to its best case.

The case against. The ethylene oxide tort docket is the dominant, partly quantified risk. The most pessimistic target, $18.00, is roughly what SHC is worth if this bites instead.

Read the full bull and bear case on SHC, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Sotera Health Company's investor relations page or your broker.

• Revenue (TTM): ~$1.22 billion for the twelve months to June 30, 2026, up ~8% from ~$1.16 billion in fiscal 2025 and ~$1.10 billion in fiscal 2024. Second-quarter 2026 revenue was $321.4 million, up 9.2% year over year and 8.0% in constant currency. On August 6, 2026 management raised full-year guidance to $1.236 billion to $1.254 billion, implying 5.25% to 6.75% constant-currency growth plus an estimated 100 basis points of currency benefit.
• Earnings and EPS: GAAP net income of ~$163.5 million for the twelve months to June 30, 2026, against $77.9 million in fiscal 2025 and $44.3 million in fiscal 2024. Trailing diluted EPS is $0.57, putting the shares near 34x reported earnings. The year-on-year comparison flatters 2026 because fiscal 2025 absorbed $64.9 million of Illinois settlement charges and heavier intangible amortization. Q2 2026 net income was $53.6 million ($0.19 diluted) versus $8.0 million ($0.03) a year earlier; adjusted EPS of $0.26 rose 30%, and full-year adjusted EPS guidance is $0.95 to $1.01.
• Segment mix and margins: For fiscal 2025, Sterigenics contributed $755.8 million of revenue (65% of the total) at a 54.6% segment margin, Nordion $187.6 million (16%) at 57.3%, and Nelson Labs $220.2 million (19%) at 33.3%. In the second quarter of 2026 those revenues were $211.6 million, $49.1 million and $60.7 million, with segment income of $118.1 million, $28.0 million and $19.6 million. Consolidated adjusted EBITDA margin was 51.6% in the quarter and 51.1% on a trailing twelve-month basis. Nelson Labs is the swing factor, having fallen 3.9% in 2025.
• Cash flow and capital spending: Net cash from operating activities was $117.9 million in the first half of 2026 versus $112.9 million a year earlier, with $88 million of it in the second quarter. Capital expenditure was $92.6 million in the half against $51.1 million in the prior-year half, and full-year 2026 guidance is $200 million to $225 million, close to 17% of revenue. Free cash flow is therefore a small fraction of the $621.6 million of trailing adjusted EBITDA, because cobalt supply, plant capacity and emissions controls all consume cash.
• Balance sheet: Total debt of ~$2.27 billion and unrestricted cash of $357.0 million at June 30, 2026, for net debt near $1.91 billion and a net leverage ratio of 3.0x, the top of the 2.0x to 3.0x target. Total assets were $3.31 billion, total liabilities $2.64 billion and total equity $665.6 million, including goodwill of $1.09 billion. Available liquidity was ~$950 million with the $600 million revolver undrawn. The May 2026 repricing set ~$1.42 billion of term loans at SOFR plus 2.25%.
• Market pricing: The shares closed at $19.57 on August 21, 2026, against a 52-week range of $13.09 to $19.85, for a market capitalization of ~$5.58 billion on ~285.4 million shares outstanding (289 million to 291 million weighted-average diluted shares guided for 2026). Enterprise value is roughly $7.5 billion, or ~12x trailing adjusted EBITDA of $621.6 million and ~11.7x the midpoint of 2026 guidance. Trailing P/E is ~34x, the forward multiple on guided adjusted EPS is ~20x, and price to trailing sales is ~4.6x. Sotera pays no dividend.

Roughly 12x enterprise value to adjusted EBITDA is a modest price for a business earning 51% EBITDA margins on largely contracted revenue from a regulated, hard-to-replicate asset base. The discount is the litigation. Sotera carries no reserve for the ~970 ethylene oxide claims still outstanding, so the multiple embeds an unpriced tail rather than a known cost. The trailing GAAP P/E of ~34x, meanwhile, reflects amortization, interest and settlement charges that the adjusted figures strip out.

Other names that sit close to SHC: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get SHC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SHC sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where SHC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

As of August 2026, Sotera Health is a high-margin, contract-heavy sterilization franchise (51.1% adjusted EBITDA margin on trailing revenue of ~$1.22 billion) that has cleared both its private equity overhang and its worst litigation quarters, while roughly 970 ethylene oxide claims remain open in Georgia and California. At ~12x enterprise value to trailing adjusted EBITDA, the market is paying for mid-single-digit organic growth against an unreserved legal tail.

Whether SHC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SHC a buy or a sell?, and where the stock could go from here in the SHC stock forecast.

For income investors, whether SHC pays a dividend and how the payout looks is covered in does SHC pay a dividend? And to weigh SHC against a peer, read the full side-by-side comparisons: SHC vs BEAM and SHC vs MDT.